Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,881 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04665635Recruiting
Ovarian cancer surgery: bowel shaving vs bowel resection
This trial compares two surgical options for ovarian cancer that involves the rectosigmoid bowel wall: removing a segment (resection) versus shaving only the involved layer (tumor shaving). It may help find which approach is safer and better for people whose cancer has spread to the outer bowel layers.
AdanaAges 18 years+ - NCT05326620Recruiting
Renal cancer patients join a Dutch research kidney study
This study enrolls people newly diagnosed with kidney cancer (including when it has spread) to help build research resources for future kidney cancer care. If you qualify, your information may be used to better understand outcomes and improve treatments.
Amsterdam, North HollandAges 18 years+ - NCT06714357RecruitingPhase 2
Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Caserta, CEAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06253494RecruitingPhase 1/Phase 2
Combination therapy trial for advanced endometrial cancer
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
Bethesda, MarylandAges 18–120 - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT07195344RecruitingPhase 4
T-DXd for breast cancer: comparing drug levels by BMI
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
AngersAges 18 years+ - NCT06771219RecruitingPhase 1
Testing SLV-154 for advanced cancers
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
Newport Beach, CaliforniaAges 12 years+ - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06110793RecruitingPhase 1/Phase 2
Study of lenvatinib, pembrolizumab, and fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) for people with a certain type of advanced breast cancer that has stopped responding to previous hormone therapy. The goal is to see if this new combination can help shrink or control the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06472804Recruiting
Insomnia in advanced lung cancer patients
This study looks at how common insomnia (trouble sleeping) is in people with advanced lung cancer. It aims to better understand sleep problems so doctors can help patients sleep better.
Rochester, MinnesotaAges 18 years+ - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT06524570RecruitingPhase 1
Focused ultrasound plus immune therapy for advanced cancer
This trial tests a new treatment that combines a special type of focused ultrasound (called histotripsy) with an immune checkpoint inhibitor to boost the immune system's attack on cancer. It is for people with advanced cancer that has not responded to standard treatments.
Utrecht, UtrechtAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT06032052RecruitingPhase 2
Chemo plus immunotherapy for older adults with metastatic lung cancer
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Wuhan, HubeiAges 65 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT04068649RecruitingPhase 2
Single high-dose radiation vs standard palliative radiation
This Phase 2 study compares a one-time, high-dose radiation treatment (SBRT) with the usual, shorter-course palliative radiation. The goal is to see which approach better relieves symptoms from metastatic (spread) cancer.
Buffalo, New YorkAges 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,881 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.